TNFRSF8 and Hodgkins lymphoma: The successful immunotherapeutic targeting of CD30 was established through brentuximab vedotin, an anti-CD30 antibody–drug conjugate (ADC) that recorded marked clinical benefits in patients with HL and some TCL subtypes [86,87].